AAAAAA
Results:
1-13
|
Results: 13
Authors:
Luck, HJ
Du Bois, A
Weber, B
Pfisterer, J
Goupil, A
Kuhn, W
Barats, JC
Blohmer, J
Mousseau, M
Schroder, W
Meier, W
Mobus, V
Richter, B
Citation: Hj. Luck et al., The integration of anthracyclines in the treatment of advanced ovarian cancer, INT J GYN C, 11, 2001, pp. 34-38
Authors:
du Bois, A
Luck, HJ
Pfisterer, J
Schroeder, W
Blohmer, JU
Kimmig, R
Moebus, V
Quaas, J
Citation: A. Du Bois et al., Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group, ANN ONCOL, 12(8), 2001, pp. 1115-1120
Authors:
Scholz, U
Luck, HJ
Canzler, U
Robner, D
Kuhnle, H
Citation: U. Scholz et al., A phase I study - UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer, ONCOLOGY-NY, 14(10), 2000, pp. 44-46
Authors:
Langer-Nitsche, C
Luck, HJ
Heilmann, M
Citation: C. Langer-nitsche et al., Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer, ACTA ONCOL, 39(8), 2000, pp. 1001-1001
Authors:
Sturm, I
Papadopoulos, S
Hillebrand, T
Benter, T
Luck, HJ
Wolff, G
Dorken, B
Daniel, PT
Citation: I. Sturm et al., Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and the p53 gene, INT J CANC, 87(4), 2000, pp. 517-521
Authors:
du Bois, A
Luck, HJ
Bauknecht, T
Pfisterer, J
Meier, W
Citation: A. Du Bois et al., Second-line chemotherapie after platinum or platinum and paclitaxel-based chemotherapy for ovarian cancer: A systematic review, GEBURTSH FR, 60(1), 2000, pp. 41-58
Authors:
du Bois, A
Schlaich, M
Luck, HJ
Mollenkopf, A
Wechsel, U
Rauchholz, M
Bauknecht, T
Meerpohl, HG
Citation: A. Du Bois et al., Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy, SUPP CARE C, 7(5), 1999, pp. 354-361
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Authors:
Luck, HJ
Scholz, U
Kuhnle, H
Dethling, J
Citation: Hj. Luck et al., UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer, ONCOLOGY-NY, 13(7), 1999, pp. 74-76
Authors:
du Bois, A
Luck, HJ
Bauknecht, T
Meier, W
Richter, B
Kuhn, W
Quaas, J
Pfisterer, J
Citation: A. Du Bois et al., First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group, J CL ONCOL, 17(1), 1999, pp. 46-51
Authors:
du Bois, A
Luck, HJ
Bauknecht, T
Citation: A. Du Bois et al., First-line chemotherapy in advanced ovarian cancer: State of the art and future aspects, ONKOLOGIE, 22(4), 1999, pp. 269-280
Authors:
Hoffken, K
Diehl, V
Kanz, L
Possinger, K
Zander, A
Kreienberg, R
Bender, HG
Elling, D
Jackisch, C
Luck, HJ
Mobus, V
Nitz, U
Thomssen, C
Untch, M
Gaisser, A
Citation: K. Hoffken et al., High dose treatment of mammary carcinoma. "Wait and see" is the reaction to the results of the randomized studies presented at the ASCO 1999 in Atlanta, GYNAKOLOGE, 32(8), 1999, pp. 655-655
Authors:
Luck, HJ
Scholz, U
Petry, KU
Bohmer, G
Kuhnle, H
Citation: Hj. Luck et al., Importance of topotecan in the therapy of ovarian carcinoma, today and tomorrow, ONKOLOGIE, 21, 1998, pp. 6-9
Risultati:
1-13
|